Second Department of Anaesthesiology and Intensive Care, Medical University of Lublin, Poland.
Department of Anaesthesiology, Intensive Care, and Regional ECMO Centre, Institute of Medical Sciences, University of Opole, Poland.
Anaesthesiol Intensive Ther. 2024;56(2):141-145. doi: 10.5114/ait.2024.139526.
Many patients required mechanical ventilation support due to severe COVID-19 pneumonia. A significant proportion of mechanically ventilated patients also required venovenous extracorporeal membrane oxygenation (VV-ECMO) due to refractory hypoxemia. A high demand for VV-ECMO support during the pandemic was challenging due to many factors, including limited resources and lack of established transfer protocols. This study aims to present the organisation and outcomes of a mobile VV-ECMO program in two high-volume centres in Poland during the COVID-19 pandemic.
This retrospective, two-centre case series study, which lasted 36 months, was conducted between March 10, 2020, and January 31, 2023. The data of all patients transferred using venovenous extracorporeal membrane oxygenation (VV-ECMO) were analysed, including five women in the perinatal period with severe respiratory failure attri-buted to the COVID-19 virus. The analysis encompassed baseline patient demographics, Sequential Organ Failure Assessment (SOFA) scores, admission laboratory parameters, ECMO therapy, duration of mechanical ventilation, and patient survival to ICU discharge.
We assessed 86 patients who met the ELSO inclusion criteria and were transported during VV-ECMO support. Mortality in the analysed group was high (80.3%). Despite high mortality, VV-ECMO appeared to be a safe procedure in COVID-19 patients with severe ARDS. No complications were noted in more than half of the analysed procedures. Despite the above, many severe complications were observed, including stroke or cerebral haemorrhage (9.8%) and limb or gut ischemia (1.6%). The most common problems co-existing with VV-ECMO treatment were bleeding complications (34.4%).
The ICU mortality rate among patients requiring VV-ECMO for COVID-19 in high-volume ECMO centres was high but not associated with the type of transportation.
由于严重的 COVID-19 肺炎,许多患者需要机械通气支持。由于难治性低氧血症,相当一部分机械通气患者也需要静脉-静脉体外膜肺氧合(VV-ECMO)。由于多种因素,包括资源有限和缺乏既定的转院协议,大流行期间对 VV-ECMO 支持的高需求具有挑战性。本研究旨在介绍波兰两个大容量中心在 COVID-19 大流行期间的移动 VV-ECMO 计划的组织和结果。
这是一项回顾性、两中心病例系列研究,持续 36 个月,于 2020 年 3 月 10 日至 2023 年 1 月 31 日进行。分析了所有使用静脉-静脉体外膜肺氧合(VV-ECMO)转院的患者的数据,包括五例围产期女性,因 COVID-19 病毒导致严重呼吸衰竭。分析包括患者人口统计学基线、序贯器官衰竭评估(SOFA)评分、入院实验室参数、ECMO 治疗、机械通气持续时间和患者存活至 ICU 出院。
我们评估了符合 ELSO 纳入标准并在 VV-ECMO 支持下转运的 86 名患者。分析组的死亡率很高(80.3%)。尽管死亡率很高,但 VV-ECMO 似乎是 COVID-19 严重 ARDS 患者的一种安全治疗方法。在分析的程序中,超过一半没有出现并发症。尽管如此,还是观察到了许多严重的并发症,包括中风或脑出血(9.8%)和肢体或肠道缺血(1.6%)。最常见的与 VV-ECMO 治疗并存的问题是出血并发症(34.4%)。
在大容量 ECMO 中心,因 COVID-19 需要 VV-ECMO 的患者的 ICU 死亡率很高,但与转院类型无关。